A recent review in Clinical Advances in Hematology & Oncology spotlights promising developments in gastrointestinal oncology — especially for colorectal and pancreatic cancers, where late-stage diagnoses have long limited options. Highlights include fruquintinib for refractory metastatic CRC, the tucatinib + trastuzumab combination for HER2-positive CRC, and expanded uses for trifluridine-tipiracil in combination regimens.
Trending
- GI 2.0: The Playbook | Chapter 3 | The Assets You Already Own
- Microbiome: Overhyped and underutilized?
- AI adoption surges, but providers worry about deskilling (Healthcare Dive)
- The gastroenterologist pay gap (Becker’s GI & Endoscopy)
- 8 No Surprises Act shake-ups physicians need to know (Becker’s Healthcare)
- ChristianaCare researchers identify genetic drivers of aggressive CRC (Becker’s GI & Endoscopy)
- A Collaborative Approach for Advanced IBD Therapy Prior Authorization Denials (GI & Endoscopy News)
- Personalized Nutrition: The Future of Gastroenterology (Grand View Research)
